Summary Serial thyroid functions studies were carried out in patients with melanoma and renal cell carcinoma treated with interleukin-2 (3 MU m-2 by continuous infusion days 1-4) and interferon a-2a (6 MU m-2 subcutaneously on days 1 and 4), both given on alternate weeks. The results on eight patients who completed at least three cycles of treatment are described. Four patients developed thyroid dysfunction with a hyperthyroid phase of 2 weeks followed by a hypothyroid phase ranging from 12 to 24 weeks. Two patients became clinically symptomatic and required treatment. Fine-needle aspirates of the thyroid were obtained in three patients with thyroid dysfunction. The considered to be 0-350 IE ml-' with 350-500 U ml-' borderline and > 500 IE ml-X elevated. Levels of anti-nuclear, anti-mitochondrial, anti-parietal and anti-islet cell antibodies were measured by indirect immunofluorescence (Kit from Zeus Scientifics Inc., Raritan, NJ, USA, and DMD AG, Schaffhausen, Switzerland).
High doses of interleukin-2 (IL-2) with or without lymphokine-activated killer (LAK) cells have been demonstrated to have antitumor activity in human melanoma and renal cell carcinoma, although at the cost of considerable acute toxicity Fisher et al., 1988; Dutcher et al., 1989; Stahel et al., 1989) . With the aim to increase the response rate and/or to reduce the IL-2 dose and toxicity without loss of efficacy alternative schedules of IL-2 in combination with other biologicals are currently being explored, including the combination of IL-2 and interferon (INF) a-2a. The rationale for this combination in melanoma and renal cell carcinoma is two-fold: (1) both IL-2 and INF a-2a have been shown to have activity against these tumours when used as single agents; and (2) in combination, these drugs have a synergistic anti-tumour effect in animal models (Brunda et al., 1986) . Various schedules of IL-2/INF a-2a are being examined by several groups of investigators. Our own ongoing phase II study investigates the tolerance and efficacy of IL-2, 3 MU m-2 by continuous infusion days 1-4 and INF a-2a 6 MU m-2 subcutaneously on days I and 4, both given on alternate weeks in patients with metastatic melanoma and renal cell carcinoma.
Subacute thyroid dysfunction has been reported in patients treated with IL-2 and LAK cells. In a series of 34 patients, retrospective laboratory analysis revealed a transient hypothyroid state in seven patients (Atkins et al., 1988) . Because of this observation all patients in our current IL-2/INF a-2a study were (Figure 2) . The fine-needle aspirates of the three patients and of three untreated controls were examined for expression of class II antigens by immunocytochemistry. Thyroid epithelial cells of all three patients revealed strong expression of HLA-DR antigen (Figure 3a) , while controls remained antigen negative (Figure 3b) . Patient I had a subclinical course which was detected only later during treatment and therefore had no biopsy done.
Functional NK and LAK activity of PNMCs and the number of PMNCs with NK markers were determined at baseline and after stimulation at day 8 of the third and three of 13 (23%) patients treated for breast cancer (Fentimann et al., 1988) . The thyroid dysfunction observed in our study is caused by an autoimmune thyroiditis, as evidenced by the evolution of thyroid function studies, the cellular infiltrates in fine-needle aspirates and by the expression of HLA class II antigens by thyroid epithelial cells. This condition evolved within 4-6 weeks of alternate weekly IL-2/INF x-2a therapy with first a hyperthyroid phase of 2 weeks duration followed by a hypothyroid phase lasting up to 24 weeks. Three patients had a fine-needle aspirate of the thyroid during the hypothyroid state and all three showed a pattern consistent with an autoimmune thyroiditis with a mixed lymphocytic/histiocytic infiltrate and strong staining of thyrocytes for HLA class II antigens. In contrast to Hashimoto's thyroiditis which is usually long lasting and often evolves into a permanent hypothyroid state (Doniach et al., 1979) , the thyroiditis observed in our patients was self-limited. initially suggested aberrant HLA class II expression on thyrocytes as a key factor for the induction of autoimmune thyroiditis. Normal thyrocytes do not express HLA class II antigens, whereas strong expression has been demonstrated in patients with autoimmune thyroiditis . In vitro, HLA class II expression can be induced on cultured human thyrocytes by adding activated T-cells or more directly recombinant INF -, (Todd et al., 1985) . TNF a enhances the effect of INF y (Buscema et al., 1989) ; recombinant IL-2 (Todd et al., 1985) or INF a (Burman et al., 1986 ) added in the absence of INF y fail to induce HLA class II on human thyrocytes. (Flynn et al., 1988 (Rasmussen et al., 1987 It is pertinent to ask why autoimmune disease has been restricted to the thyroid and why only selected patients were afflicted. In general there appears to be a genetic basis for the tendency to develop autoimmunity as evidenced by HLA associations and family studies which are also indicative for a preference for a particular organ (Flynn et al., 1988) . In experimental models a restricted usage of some T cell receptor VP3 genes in the T cell response to defined determinants on autoantigens had been shown (Zamvil et al., 1988 ). An individual disease susceptibility has been suggested by the observation of genetic differences in the amount of MHC class II expression following IFN y treatment of parenchymal cells (Massa et al., 1987) .
HLA class II antigen expression on tumour cells has been found associated with responsiveness to IL-2 and LAK cell therapy and an association between hypothyroidism and tumour response to IL-2 and LAK cells has been suggested (Cohen et al., 1987) . This hypothesis is also supported by our preliminary observations together with a group of investigators in Dublin with four tumour responses to IL-2/INF a-2a treatment (two minor and two partial) in eight patients with hypothyroidism, and no responses in seven euthyroid patients (communicated by Pichert et al., 1989) . Together these observations suggest that the expression of HLA class II antigens and auto-reactive cytotoxic T-lymphocytes might contribute to the development of thyroiditis as well as to the anti-tumour response, in addition to NK and LAK cells which act independent of the HLA class II system.
Self-limited thyroiditis with hyperthyroidism followed by hypothyroidism occurs in half of the patients treated with IL-2 and INF a-2a. Clinical or laboratory thyroid dysfunction should be anticipated in future clinical trials with these substances. Also the possibility of a positive correlation between tumour response and the occurrence of thyroiditis needs further evaluation.
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